Indivior PLC(INDV) - 2023 Q3 - Earnings Call Presentation

• INDV 2000 (OUD3): Phase 1 study MAD6 LSLV in Q3-2023, Successful endof-Phase 1 meeting with FDA in Q4- 20235 • INDV 4002 (AUD3): Phase 2 data Q4- 20235 Q3 2023 financial highlights Key Takeaways (vs. Q3 2022) ➤ Reported SG&A expenses driven by litigation provision; Adjusted SG&A expenses up 33% reflecting increased legal costs, Opiant and OPVEE launch expenses, SUBLOCADE commercial investments and cost inflation 2 See reconciliation pages in the appendix 3 Actual FX (foreign exchange) rates Cash & Borrowi ...